The growing biologics market, affordability and sustainability of single-use bioprocess technologies, and rising biopharmaceutical RD. Emerging countries and the patent expiry of biologics are expected to offer growth opportunities for players operating in the bioprocess containers market during the forecast period.
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has since moved from being a regional crisis to a global pandemic. With the World Health Organization (WHO) officially declared the outbreak of the virus as a pandemic, a mix of established pharmaceutical companies.
Most of the pandemic-related new facilities are largely engaging single-use systems due to their flexibility combined with high speed and much lower capital investment compared to traditional stainless steel equipment.
For More Information, Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107645832
The growth of single-use technologies can be attributed to the growing need for better, cheaper, and faster biologics production. Active development of individualized biologics and personalized medicines, including patient-specific cellular gene therapies and therapeutic vaccines, demands high sterility and is therefore manufactured using single-use equipment and consumables.
Additionally, the Centre for Biologics Evaluation and Research’s (CBER) (2021-25) strategic plan involves various schemes for boosting the growth of the biologics market. With increasing growth in the biologics market, the number of bioprocess containers needed for RD and biologics manufacturing is also expected to increase in the coming years.
Extractables are compounds that can be extracted from source materials using appropriate solvents under vigorous laboratory conditions, while leachables are compounds present in drug products caused by leaching from containers, closures, and processing components.
The 2D bioprocess containers segment accounted for the largest share of the type segment in the bioprocess containers market in 2020.
On the basis of type, the bioprocess containers market is segmented into 2D bioprocess containers, 3D bioprocess containers, and other containers and accessories. In 2020, the 2D bioprocess containers segment accounted for the largest share of the bioprocess containers market.
According to a survey conducted by BioPlan Associates in 2018, 73.3% of respondents agreed that leachables and extractables are major concerns that may limit the use of bioprocessing in the near future. As single-use assembly products are made of processed plastic materials, they often face the problem of contamination from the container due to leachables.
As many patented products are going off-patent in the future, companies are falling short of funds to invest in their RD pipelines. According to data published in the Generics and Biosimilars Initiative Journal, around twelve biological products with global sales of more than USD 67 billion will be exposed to biosimilar competition by 2020.
The patent expiry of blockbuster drugs has resulted in increased RD spending by pharmaceutical and biotechnology companies. Patent expiry of biologics leads to increasing RD of biologics and shifts biologics from the pipeline to commercial production. As the development and manufacturing costs of biologics are very high, companies are now gradually focusing on techniques that are more economical than traditional biomanufacturing methods.
Read Full Press Release @ https://www.prnewswire.com/news-releases/bioprocess-containers-market-worth-9-6-billion-by-2026--exclusive-report-by-marketsandmarkets-301386429.html
